文献速递艾滋病与性传播感染结核与非结核分枝杆菌

HIV相关结核患者接受比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺与利福平治疗时每日两次替诺福韦艾拉酚胺的药代动力学

Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该研究为INSIGHT试验干预臂的半密集药代动力学亚组研究,纳入43例接受BIC/FTC/TAF(50/200/25 mg)的HIV相关结核患者,在利福平治疗期间每日两次给药、之后每日一次给药。结果显示每周12次给药相对每周32次给药的TAF、TFV和TFV-DP暴露几何均值比分别为1.55、1.24和1.32,95%患者实现病毒抑制,无治疗相关严重不良事件或停药。

要点

  • 利福平治疗期间每日两次TAF可使细胞内TFV-DP暴露与每日一次TAF单用时相似。
  • 每日两次TAF在HIV相关结核患者中安全有效,95%实现病毒抑制。
  • 数据支持在含利福平的结核治疗期间使用BIC/FTC/TAF固定剂量组合。

核心结论

  • 每日两次TAF在服用利福平的HIV相关结核患者中安全有效,细胞内TFV-DP暴露与每日一次TAF单用时相似。

研究设计与样本

  • INSIGHT试验(NCT04734652)干预臂的半密集药代动力学亚组研究,纳入43例接受BIC/FTC/TAF(50/200/25 mg)的HIV相关结核患者。
  • 利福平治疗期间(约24周)每日两次给药,之后每日一次给药;在治疗第4、12周及第32周采集血浆和干血斑样本。

主要发现

  • 第12周(每日两次TAF)相对第32周(每日一次TAF)的TAF AUC0-4、TFV和TFV-DP AUC0-24几何均值比(90% CI)分别为1.55(1.13-2.13)、1.24(1.07-1.44)和1.32(1.13-1.53)。
  • 第24周95%的参与者实现病毒抑制,无治疗相关严重不良事件或药物停药。

临床怎么用

  • 在含利福平的结核治疗期间,可考虑使用BIC/FTC/TAF固定剂量组合并采用每日两次TAF给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tenofovir alafenamide (TAF) is a key component of many fixed-dose combinations used to treat HIV. There are limited data on the pharmacokinetics of plasma TAF, tenofovir (TFV), or intracellular tenofovir diphosphate (TFV-DP), among people with HIV (PWH) and tuberculosis (TB) who are taking rifampicin-based TB treatment. METHODS: Participants in the intervention arm of the INSIGHT trial (NCT04734652) receiving bictegravir/emtricitabine/TAF (BIC/FTC/TAF 50/200/25 mg) were enrolled into the semi-intensive pharmacokinetic substudy. BIC/FTC/TAF was administered twice-daily during rifampicin-based TB treatment (∼24 weeks) and once-daily thereafter. Plasma (TAF/TFV) and dried blood spot samples (TFV-DP) were collected at weeks 4 and 12 (predose, 1, 2, 4, 6, and 8-12 hours postdose) during TB treatment and at week 32 (predose, 1, 2, 4, 6-8 and 24-25 hours postdose) post-TB treatment. Pharmacokinetic parameters were determined using noncompartmental analysis. Clinical and safety data were collected. RESULTS: Among 43 participants enrolled; median (IQR) age and weight were 35 (30-39) years and 58 (52-65) kg; 77% were male. Geometric least square mean ratios (90% CI) at week 12 (twice-daily TAF) relative to week 32 (once-daily TAF) for TAF AUC0-4, TFV, and TFV-DP AUC0-24 were 1.55 (1.13-2.13), 1.24 (1.07-1.44), and 1.32 (1.13-1.53), respectively. At week 24, 95% of participants achieved viral suppression, with no treatment-related serious adverse events or drug discontinuations. CONCLUSIONS: Twice-daily TAF was safe and efficacious and achieved similar exposures of intracellular TFV-DP in PWH taking rifampicin for TB compared to once-daily TAF taken alone. These data support the use of TAF in a fixed-dose combination of BIC/FTC/TAF during rifampicin-containing TB treatment.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Osuala EC, Nkuhairwe IN, Letsoalo MP, et al. Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin. Clin Infect Dis. 2026. PMID: 41467354. doi:10.1093/cid/ciaf732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。